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Abstract: Vasomotor symptoms (VMS) are among the most bothersome complaints of 
postmenopausal women. To date, the most widely studied and effective treatment for VMS is 
hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen 
plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for 
  treatment. However, over the years, additional estrogen formulations have been developed 
including transdermal patches; vaginal rings, creams, and tablets; and injectable preparations. 
Two newer formulations are transdermal estrogen spray and estradiol topical emulsion. This 
review evaluates the current literature assessing the use of these two newer formulations for 
the treatment of VMS associated with menopause.
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Introduction
Although all women will be subject to menopause and the cessation of menses, not 
all women will experience its associated symptoms. Of the associated symptoms, 
vasomotor symptoms (VMS) are the most bothersome. They may include hot flashes 
(rapid onset of intense heat sensation, sweating, and flushing lasting approximately 5 to 
10 minutes) and/or night sweats.1–3 They are the leading reason menopausal women 
seek medical care as can be illustrated by a 2002 Gallup poll of menopausal women 
showing that hot flashes, night sweats, mood disturbances, and sleep disturbances were 
the top four reasons for which medical attention was sought at this time in their lives.4 
Overall, VMS are estimated to affect 14% to 51% of premenopausal women, 35% to 
50% of perimenopausal women, and 30% to 80% of postmenopausal women.3
On average, most women experience VMS for 6 months to 2 years; however, 
approximately 10% of women report experiencing VMS for 10 or more years.4,5
In total, it is estimated that 60% of peri- and postmenopausal women seek care for 
their menopausal symptoms.6
VMS
There is currently no consensus on the pathophysiology of menopause-associated VMS; 
however several mechanisms have been proposed. One is a narrowing of the thermoregu-
latory threshold between sweating and shivering in the hypothalamus.7 This narrowing 
is thought to be caused by decreased levels of circulating serotonin, increased levels 
of norepinephrine, and/or decreased estrogen concentrations.1,5 The perimenopausal 
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on the anterior pituitary, leading to a compensatory increase 
in the secretion of   leuteinizing hormone from the pituitary, 
a process regulated by   gonadotropin-releasing hormone in the 
hypothalamus.8 Pulsatile surges of   gonadotropin-releasing 
hormone due to estrogen deficiency affect the hypothalamic 
neurons that control central thermoregulation centers.9
It has also been hypothesized that the ratios of the   specific 
types of estrogen (ie, estradiol or estrone) may be better 
  correlated with the occurrence of VMS than the overall 
circulating level of estrogen.10 Compared to   premenopausal 
women in whom the most abundant   circulating estrogen 
is estradiol, the more potent form of estrogen, throughout 
the peri- and postmenopausal years, the most abundant 
  circulating estrogen shifts to estrone, a much less potent form 
of estrogen.8 Further, the occurrence of VMS has been found 
to correlate better with an acute decline in estrogen levels 
than with the actual measured levels of estrogen.5
Estrogen therapy (ET)
Given the above proposed mechanisms for VMS, it is no 
  surprise that hormone replacement therapy (HT),   consisting of 
estrogen (in women without a uterus) or estrogen plus   progestin 
(in women with a uterus [to protect against   endometrial 
  hyperplasia or cancer]), is the most widely   studied and most 
effective treatment option for relieving VMS and is   considered 
the standard of care for women with moderate-to-severe 
VMS.1,2 The AACE and ACOG recommend the use of HT at 
the lowest effective dose and for the shortest duration   possible 
(preferably #5 years) in women for whom the   potential ben-
efits outweigh the potential risks.1,11 The 5-year cut-off for 
HT is suggested because most women will experience spon-
taneous cessation of menopausal symptoms within 5 years of 
onset.1 Use of HT for longer durations may be   appropriate in 
some women, such as those who judge the   benefits of VMS 
relief to outweigh the potential risks after f  ailing an attempt 
to discontinue HT, those with continued VMS who are also 
at high risk for osteoporotic fractures, and those requiring 
osteoporosis prevention who cannot take   alternative therapies.2 
Several weeks may be required to   determine the efficacy of HT 
in treating VMS.5 Contraindications to the use of HT include 
breast or estrogen-sensitive cancers, undiagnosed vaginal 
bleeding, endometrial hyperplasia, blood clotting disorder, 
hypertension, liver disease, hypersensitivity to the active or 
excipient compounds in HT.1
The recommendation that HT is the standard of care 
for treating moderate-to-severe VMS is based on the 
large body of evidence demonstrating the effectiveness 
of estrogen or estrogen plus progestin in the reduction of 
VMS frequency and   severity. In fact, a meta-analysis of 
24 double-blind,   randomized, placebo-controlled trials 
including a total of 3,329 subjects and ranging in duration 
from 3 months to 3 years demonstrated a significant 75.3% 
reduction in the   frequency of hot flashes experienced per 
week (weighted mean difference, −17.92, 95% confidence 
interval [CI], −22.86 to −12.99) and a significant 87% reduc-
tion in the severity of symptoms (odds ratio [OR], 0.13; 95% 
CI, 0.07 to 0.23) relative to placebo. The most frequently 
used HT regimens noted in the   meta-analysis included 
oral   estradiol, conjugated equine estrogens, and   ethinyl 
estradiol, with or without a 19-nor   testosterone   derivative.12 
These   relative reductions are significant   considering that 
the placebo response rate in this meta-analysis was 57.7%. 
There are   currently no data available to suggest that any 
one   formulation of estrogen or estrogen plus progestin is 
clinically superior to another.5,11,13 Estrogen and   progestin are 
available in various oral,   transdermal (patch, spray, and emul-
sion), vaginal, and injectable preparations. Table 1   illustrates 
the recommended doses for these   various products.
Table 1 Recommended dosing ranges for commonly used hormonal therapies used to treat vasomotor symptoms1,2,5,14
Drug Daily dose 
Estrogens
  Conjugated equine estrogens  0.3–0.625 mg
  Micronized 17β-estradiol 0.25–1 mg
  Transdermal estradiol (patch) 14–100 μg
  Transdermal estradiol (spray) 1.53–4.59 mg
Transdermal estradiol (emulsion) 3.84 g
Ethinyl estradiol 0.01–0.02 mg
vaginal estradiol ring 0.05–0.1 mg
Progestins
  Medroxyprogesterone acetate  2.5 mg (or 5 mg for 10–14 days/month)
  Micronized progesterone 100 mg (or 200 mg for 10–14 days/month)
  Norethindrone 0.14–0.25 mg (transdermal patch); 0.2–1 mg (orally)
  Levonorgestrel 0.075 mgInternational Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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ET dosage formulations
Traditionally, ET has been administered orally. However, 
other routes of ET administration have been developed. 
Transdermal formulations, such as the patch, spray and 
topical emulsion, offer some advantages over oral estradiol 
administration. These formulations avoid hepatic first pass 
metabolism that is observed with the oral formulations and 
that can result in the variable bioavailability of estrogen 
and potentially the need for higher doses. In addition, these 
  dosage formulations have little or no risk for the   development 
of conditions such as hypertriglyceridemia, gallbladder 
  disease, and thromboembolism.15,16
However, while the transdermal administration bypasses 
first pass metabolism and results in effective therapy at lower 
estrogen doses, some concerns with this delivery system 
do exist. These include variable systemic   absorption, skin 
irritation, and poor adhesion of the patches.17–19 Two newer 
formulations, transdermal spray and topical   emulsion, may 
offer some advantages over both the orally administered and 
transdermal patch estrogen. This review examines the clinical 
data related to the use of the   transdermal spray and topical 
emulsion ET to treat VMS associated with menopause.
ET – transdermal spray  
and topical emulsion
Presented here are summaries of the clinical trials evaluating 
the effects of transdermal estrogen spray and estradiol topical 
emulsion on VMS associated with menopause.
ET – transdermal spray
The transdermal estrogen spray is a clear spray that dries in 
60 seconds and results in little to no skin irritation.20 It has been 
shown that significant transfer of estradiol via   skin-to-skin 
contact does not occur; washing the application site 1 hour after 
application does not affect absorption; and applying sunscreen 
1 hour prior to application also does not affect absorption.21
In a phase III, randomized, double-blind,   placebo-controlled, 
parallel-group trial, Buster et al   investigated the safety and effi-
cacy of a transdermal e  stradiol spray.20 Postmenopausal women 
(n = 454) with at least 8 moderate-to-severe hot flashes per day 
(recorded in a daily diary) were randomly assigned to receive 
1, 2, or 3 sprays of estradiol; or 1, 2, or 3 sprays of placebo to 
the inner forearm. One spray of estradiol delivered 1.52 mg of 
estradiol. The primary efficacy endpoint was the change in fre-
quency and severity (0, none; 1, mild; 2, moderate; or 3, severe) 
of moderate-to-severe hot flashes from baseline to weeks 4 and 
12. For the 3 spray group, there was a   reduction in the frequency 
of hot flashes per day of −6.64 ± 4.23 at week 4 and a reduction 
of −8.44 ± 4.50 at week 12. This was statistically significant 
when compared to placebo (P , 0.001). Similar results were 
observed in the 2 spray group, with a frequency reduction of 
−7.30 ± 6.93 at week 4 (P = 0.003) and −8.66 ± 6.65 at week 12 
(P = 0.010). There was also a   statistically significant reduction of 
hot flashes from baseline in the 1 spray group with a frequency 
  reduction of −6.26 ± 4.01 (P = 0.001) at week 4 and −8.10 ± 4.02 
(P , 0.001) at week 12 compared to placebo.
For the 3 spray group, changes in the severity score of the 
moderate-to-severe hot flashes decreased from 2.58 ± 0.25 
at baseline to 2.15 ± 0.73 and 1.50 ± 1.06 at weeks 4 and 
12, respectively. These findings were statistically significant 
(week 4, P = 0.003; week 12, P , 0.001) when compared to 
placebo (baseline, 2.54 ± 0.24; week 4, 2.41 ± 0.58; week 12, 
2.23 ± 0.79). Similar results were observed in the 2-spray 
group with the severity score being 1.97 ± 0.87 at week 4 
and 1.63 ± 1.07 at week 12 compared to a baseline score 
of 2.54 ± 0.21. These results were statistically significant 
(week 4, P = 0.016; week 12, P = 0.041) when compared to 
placebo (baseline, 2.54 ± 0.21; week 4, 2.29 ± 0.71; week 12, 
2.00 ± 0.96). For the 1-spray group, at week 12, the severity 
decreased by −1.04 compared to −0.26 ± 0.60 in the placebo 
group (P , 0.001) and there was a trend towards significance 
at week 4 (P = 0.057). It was also shown that 74.3% to 85.5% 
of women treated with transdermal estradiol spray had a $50% 
reduction in hot flash frequency when compared to baseline. 
The Greene Climacteric Scale scores, focusing on the vaso-
motor domains of hot flashes and night sweats, also showed a 
significant improvement in VMS for those women treated with 
the transdermal estradiol spray. While the baseline and week 12 
scores were not reported, it was noted that in the 3 spray group, 
there was a reduction of 1.7 in the hot flush score compared 
to 0.9 in the placebo group (P , 0.001); in the 2-spray group, 
there was a reduction of 1.3 compared to 0.9 with placebo 
(P = 0.018); and in the in the 1-spray group, there was a reduc-
tion of 1.3 compared to 0.8 with placebo (P = 0.003). All of 
these results were statistically significant.
The most common adverse events reported were head-
ache and breast tenderness. There were no reports of death, 
  pulmonary emboli, venous thromboemboli, myocardial 
infarction, or stroke. The spray was associated with little to 
no erythema. Overall, the transdermal estradiol spray was 
found to be safe and effective in the treatment of VMS.20
ET – topical emulsion
Another alternative to current ET formulations is the micel-
lar nanoparticle estradiol emulsion that is applied as a 
topical lotion. The emulsion has moisturizing qualities and International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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when applied to the skin, forms a drug depot. The estradiol 
g  radually diffuses through the skin and into the blood stream. 
The pharmacokinetic profile has shown minimal fluctuations 
in estradiol serum levels.22
In a phase III, multicenter, randomized, double-blind, 
  placebo-controlled trial, Simon and the Estrasorb Study group 
investigated the safety and efficacy of a topical   estradiol 
emulsion.22 Postmenopausal women (n = 200) with 120 or 
more moderate-to-severe hot flashes over a 2-week period 
were randomly assigned to receive placebo   emulsion or 
estradiol topical emulsion (8.6 mg of 17β-estradiol in 3.45 g 
of emulsion) to be applied daily to the thigh and calf of both 
legs until fully absorbed for 12 weeks. The primary efficacy 
endpoint was the change in frequency of   moderate-to-severe 
hot flashes from baseline to weeks 4 and 12. There was a 
significant decrease in the frequency of hot flashes per day at 
week 4 (P , 0.05) which continued throughout the treatment 
period with the peak reduction seen at week 12 (−11.1 ± 6.8 
hot flashes/day for estradiol treatment arm versus −7.2 ± 5.4 
for placebo, P , 0.001).
The secondary efficacy endpoint was the change in the 
severity of hot flashes using a severity score index. Hot 
flashes were rated as: grade 1 mild, grade 2 moderate, or grade 
3 severe. Statistically significant decreases in the daily sever-
ity score index was observed at weeks 4, 8 and 12 (P , 0.001) 
for the estradiol treatment arm versus placebo.
The most common adverse events reported in the 
t  reatment arm were endometrial/uterine wall thickening, 
infection, breast pain, application-site reaction, pruritis, 
vaginal bleeding and vaginal moniliasis. Overall, the estradiol 
topical emulsion was found to be safe and effective in the 
treatment of VMS.22
While the estradiol emulsion was found to be safe 
and effective in the treatment of VMS, in order to have 
this effect, large doses of the estrogen hormone must be 
applied   topically. This raises concerns as to whether or not 
the   hormone may be transferred to others via skin-to-skin 
contact. An   open-labeled, nonrandomized clinical study 
  performed by Taylor et al investigated the systemic 
  absorption of estradiol in partners of postmenopausal 
women. Fourteen   postmenopausal women and their partners 
were enrolled in the study. The women applied 1.74 g of 
estradiol topical emulsion (containing 2.5 mg of estradiol 
per gram) to the thigh and calf of both legs for 2 consecu-
tive days. Two hours after application, the male partner 
rubbed his left forearm vigorously back and forth across 
the application site for 2 minutes. This was repeated on the 
male’s right forearm 8 hours after application. Serum con-
centrations of estradiol, estrone, and estrone sulfate were 
measured prior to estradiol application and at 1, 2 and 8 
hours after   application for the females, and at 1, 2, 4, 8, 12, 
18 and 24 hours after their   partners had attempted transfer 
of the estradiol topical   emulsion. Geometric means analysis 
showed that the area under the serum   concentration-time 
curve from 1 to 8 hours (AUC1–8) and the maximum con-
centration (Cmax) for estradiol, estrone, and estrone sulfate 
increased 2- to 3-fold after the second a  pplication. These 
results were   statistically   significant.   Geometric means 
analysis also showed a   significant increase in the area 
under the serum concentration-time curve from 0–24 hours 
(AUC0–24) and Cmax for estradiol, estrone, and estrone sulfate 
in the male partners on day 2 when compared to baseline. 
In particular, the concentration of estradiol increased 25% 
from 17.0 ± 4.3 to 21.0 ± 4.4 pg/mL.   However, these levels 
still remained below the upper limit of the normal range for 
men (45 pg/mL).23
Summary
A variety of estrogen formulations exist for the treatment of 
menopause-related VMS. Clinical trials have demonstrated 
that transdermal spray delivery and topical emulsion are 
both effective methods for this indication and appear to be 
safe for use in postmenopausal women. In addition, both 
of these formulations avoid first pass metabolism that may 
likely result in more consistent absorption, more predictable 
estrogen concentrations, and easier dosage adjustments when 
needed. The transdermal estradiol spray was well tolerated 
by women with headache and breast tenderness being the 
most commonly reported adverse events.20 While the   topical 
estradiol emulsion is effective at decreasing VMS, more 
  studies need to be done to assess skin-to-skin transfer in more 
detail. The current data is very limited and only observed 
transfer after two applications. It is unknown what effects 
the consistent use over time may have on transfer to one’s 
partner. Overall, the transdermal estrogen sprays and topical 
estradiol emulsion are effective and acceptable alternatives 
to traditional oral and transdermal patch estrogen used in the 
treatment of VMS in postmenopausal women.
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